• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Prexton Therapeutics - Articles and news items

epr-logo

Prexton successfully completes phase 1 Parkinson’s disease trial

Industry news / 20 September 2016 / Niamh Louise Marriott, Digital Content Producer

This study was the first in man Phase 1 clinical trial for an mGluR4 positive allosteric modulator. The randomised, double-blind, placebo controlled single and multiple ascending dose studies were designed to assess safety and tolerability of PXT002331 dosed orally…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +